Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632276 | 0.90 | PTGDR2 (0.72) | PTGDR2NR1H2NR1H3 | |
| SCHEMBL28237487 | 0.86 | PTGDR2 (0.76) | PTGDR2 | |
| Fevipiprant SCHEMBL1940595 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| Fevipiprant SCHEMBL29355753 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL21632133 | 0.84 | PTGDR2 (0.72) | PTGDR2NR1H2NR1H3 | |
| SCHEMBL21695121 | 0.83 | PTGDR2 (0.69) | PTGDR2 | |
| SCHEMBL1940778 | 0.83 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL21591931 | 0.83 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL20508235 | 0.83 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL21632349 | 0.82 | PTGDR2 (0.62) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | MMAB, PAH, CPS1 | PTGDR2 2091/4885NR1H2 4840/4885NR1H3 4832/4885 |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | MMAB, PAH, CPS1 | PTGDR2 2091/4885NR1H2 4840/4885NR1H3 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.